LinkedIn

 آمار

تعداد نشریات20
تعداد شماره‌ها1,113
تعداد مقالات10,208
تعداد مشاهده مقاله40,771,376
تعداد دریافت فایل اصل مقاله8,800,546
Abadi, Banafshe, Aarabi Jeshvaghani, Hossein, Fathalipour, Hadis, Dehghan, Leili, Rahimi Sirjani, Kosar, Forootanfar, Hamid. (1401). Therapeutic Strategies in the Fight against COVID-19: From Bench to Bedside. سامانه مدیریت نشریات علمی, 47(6), 517-532. doi: 10.30476/ijms.2021.92662.2396
Banafshe Abadi; Hossein Aarabi Jeshvaghani; Hadis Fathalipour; Leili Dehghan; Kosar Rahimi Sirjani; Hamid Forootanfar. "Therapeutic Strategies in the Fight against COVID-19: From Bench to Bedside". سامانه مدیریت نشریات علمی, 47, 6, 1401, 517-532. doi: 10.30476/ijms.2021.92662.2396
Abadi, Banafshe, Aarabi Jeshvaghani, Hossein, Fathalipour, Hadis, Dehghan, Leili, Rahimi Sirjani, Kosar, Forootanfar, Hamid. (1401). 'Therapeutic Strategies in the Fight against COVID-19: From Bench to Bedside', سامانه مدیریت نشریات علمی, 47(6), pp. 517-532. doi: 10.30476/ijms.2021.92662.2396
Abadi, Banafshe, Aarabi Jeshvaghani, Hossein, Fathalipour, Hadis, Dehghan, Leili, Rahimi Sirjani, Kosar, Forootanfar, Hamid. Therapeutic Strategies in the Fight against COVID-19: From Bench to Bedside. سامانه مدیریت نشریات علمی, 1401; 47(6): 517-532. doi: 10.30476/ijms.2021.92662.2396

Therapeutic Strategies in the Fight against COVID-19: From Bench to Bedside

Iranian Journal of Medical Sciences
مقاله 3، دوره 47، شماره 6، بهمن 2022، صفحه 517-532    اصل مقاله (861.36 K)
نوع مقاله: Review Article
شناسه دیجیتال (DOI): 10.30476/ijms.2021.92662.2396
نویسندگان
Banafshe Abadi1، 2؛ Hossein Aarabi Jeshvaghani3؛ Hadis Fathalipour1، 3؛ Leili Dehghan4؛ Kosar Rahimi Sirjani3؛ Hamid Forootanfar* 5، 4
1Pharmaceutical Sciences and Cosmetic Products Research Center, Kerman University of Medical Sciences, Kerman, Iran
2Brain Cancer Research Core, Universal Scientific Education and Research Network, Tehran, Iran
3Student Research Committee, Kerman University of Medical Sciences, Kerman, Iran
4Department of Pharmaceutical Biotechnology, School of Pharmacy, Kerman University of Medical Sciences, Kerman, Iran
5Pharmaceutical Sciences and Cosmetic Products Research Center, Kerman University of Medical Sciences, Kerman, Iran
چکیده
In December 2019, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in China. This virus rapidly spread worldwide and was declared a global pandemic by the World Health Organization (WHO) in March 2020. High incidence, long incubation period, and diverse clinical signs of the disease posed a huge challenge globally. The efforts of health systems have been focused on repurposing existing drugs or developing innovative therapies to reduce the morbidity and mortality associated with SARS-CoV-2. In addition, most of the large pharmaceutical companies are intensely working on vaccine development to swiftly deliver safe and effective vaccines to prevent further spread of the virus. In this review, we will discuss the latest data on therapeutic strategies undergoing clinical trials. Additionally, we will provide a summary of vaccines currently under development. 
کلیدواژه‌ها
Coronavirus؛ COVID-19؛ Immunization؛ Passive؛ Cell- and tissue-based therapy؛ COVID-19 vaccines
سایر فایل های مرتبط با مقاله
مراجع
  1. Zheng YY, Ma YT, Zhang JY, Xie X. COVID-19 and the cardiovascular system. Nat Rev Cardiol. 2020;17:259-60. doi: 10.1038/s41569-020-0360-5. PubMed PMID: 32139904; PubMed Central PMCID: PMCPMC7095524.
  2. Netea MG, Giamarellos-Bourboulis EJ, Dominguez-Andres J, Curtis N, van Crevel R, van de Veerdonk FL, et al. Trained Immunity: a Tool for Reducing Susceptibility to and the Severity of SARS-CoV-2 Infection. Cell. 2020;181:969-77. doi: 10.1016/j.cell.2020.04.042. PubMed PMID: 32437659; PubMed Central PMCID: PMCPMC7196902.
  3. Devaux CA, Rolain JM, Colson P, Raoult D. New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19? Int J Antimicrob Agents. 2020;55:105938. doi: 10.1016/j.ijantimicag.2020.105938. PubMed PMID: 32171740; PubMed Central PMCID: PMCPMC7118659.
  4. Tan M, Liu Y, Zhou R, Deng X, Li F, Liang K, et al. Immunopathological characteristics of coronavirus disease 2019 cases in Guangzhou, China. Immunology. 2020;160:261-8. doi: 10.1111/imm.13223. PubMed PMID: 32460357; PubMed Central PMCID: PMCPMC7283723.
  5. Rothan HA, Byrareddy SN. The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak. J Autoimmun. 2020;109:102433. doi: 10.1016/j.jaut.2020.102433. PubMed PMID: 32113704; PubMed Central PMCID: PMCPMC7127067.
  6. Tufan A, Avanoglu Guler A, Matucci-Cerinic M. COVID-19, immune system response, hyperinflammation and repurposing antirheumatic drugs. Turk J Med Sci. 2020;50:620-32. doi: 10.3906/sag-2004-168. PubMed PMID: 32299202; PubMed Central PMCID: PMCPMC7195984.
  7. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395:497-506. doi: 10.1016/S0140-6736(20)30183-5. PubMed PMID: 31986264; PubMed Central PMCID: PMCPMC7159299.
  8. Mason RJ. Pathogenesis of COVID-19 from a cell biology perspective. Eur Respir J. 2020;55. doi: 10.1183/13993003.00607-2020. PubMed PMID: 32269085; PubMed Central PMCID: PMCPMC7144260.
  9. Cameron MJ, Bermejo-Martin JF, Danesh A, Muller MP, Kelvin DJ. Human immunopathogenesis of severe acute respiratory syndrome (SARS). Virus Res. 2008;133:13-9. doi: 10.1016/j.virusres.2007.02.014. PubMed PMID: 17374415; PubMed Central PMCID: PMCPMC7114310.
  10. Jacques FH, Apedaile E. Immunopathogenesis of COVID-19: Summary and Possible Interventions. Front Immunol. 2020;11:564925. doi: 10.3389/fimmu.2020.564925. PubMed PMID: 33072103; PubMed Central PMCID: PMCPMC7533543.
  11. Colson P, Rolain JM, Raoult D. Chloroquine for the 2019 novel coronavirus SARS-CoV-2. Int J Antimicrob Agents. 2020;55:105923. doi: 10.1016/j.ijantimicag.2020.105923. PubMed PMID: 32070753; PubMed Central PMCID: PMCPMC7134866.
  12. Savarino A, Boelaert JR, Cassone A, Majori G, Cauda R. Effects of chloroquine on viral infections: an old drug against today’s diseases? Lancet Infect Dis. 2003;3:722-7. doi: 10.1016/s1473-3099(03)00806-5. PubMed PMID: 14592603; PubMed Central PMCID: PMCPMC7128816.
  13. Salata C, Calistri A, Parolin C, Baritussio A, Palu G. Antiviral activity of cationic amphiphilic drugs. Expert Rev Anti Infect Ther. 2017;15:483-92. doi: 10.1080/14787210.2017.1305888. PubMed PMID: 28286997; PubMed Central PMCID: PMCPMC7103695.
  14. Vincent MJ, Bergeron E, Benjannet S, Erickson BR, Rollin PE, Ksiazek TG, et al. Chloroquine is a potent inhibitor of SARS coronavirus infection and spread. Virol J. 2005;2:69. doi: 10.1186/1743-422X-2-69. PubMed PMID: 16115318; PubMed Central PMCID: PMCPMC1232869.
  15. Tang W, Cao Z, Han M, Wang Z, Chen J, Sun W, et al. Hydroxychloroquine in patients mainly with mild to moderate COVID–19: an open–label, randomized, controlled trial. medRxiv. 2020. doi: 10.1101/2020.04.10.20060558.
  16. Axfors C, Schmitt AM, Janiaud P, Van’t Hooft J, Abd-Elsalam S, Abdo EF, et al. Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative meta-analysis of randomized trials. Nat Commun. 2021;12:2349. doi: 10.1038/s41467-021-22446-z. PubMed PMID: 33859192; PubMed Central PMCID: PMCPMC8050319.
  17. Arabi YM, Shalhoub S, Mandourah Y, Al-Hameed F, Al-Omari A, Al Qasim E, et al. Ribavirin and Interferon Therapy for Critically Ill Patients With Middle East Respiratory Syndrome: A Multicenter Observational Study. Clin Infect Dis. 2020;70:1837-44. doi: 10.1093/cid/ciz544. PubMed PMID: 31925415; PubMed Central PMCID: PMCPMC7108209.
  18. Poutanen SM, Low DE, Henry B, Finkelstein S, Rose D, Green K, et al. Identification of severe acute respiratory syndrome in Canada. N Engl J Med. 2003;348:1995-2005. doi: 10.1056/NEJMoa030634. PubMed PMID: 12671061.
  19. Gong WJ, Zhou T, Wu SL, Ye JL, Xu JQ, Zeng F, et al. A retrospective analysis of clinical efficacy of ribavirin in adults hospitalized with severe COVID-19. J Infect Chemother. 2021;27:876-81. doi: 10.1016/j.jiac.2021.02.018. PubMed PMID: 33676844; PubMed Central PMCID: PMCPMC7894089.
  20. Chu CM, Cheng VC, Hung IF, Wong MM, Chan KH, Chan KS, et al. Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings. Thorax. 2004;59:252-6. doi: 10.1136/thorax.2003.012658. PubMed PMID: 14985565; PubMed Central PMCID: PMCPMC1746980.
  21. Patel TK, Patel PB, Barvaliya M, Saurabh MK, Bhalla HL, Khosla PP. Efficacy and safety of lopinavir-ritonavir in COVID-19: A systematic review of randomized controlled trials. J Infect Public Health. 2021;14:740-8. doi: 10.1016/j.jiph.2021.03.015. PubMed PMID: 34020215; PubMed Central PMCID: PMCPMC8056786.
  22. Amani B, Khanijahani A, Amani B, Hashemi P. Lopinavir/Ritonavir for COVID-19: a Systematic Review and Meta-Analysis. J Pharm Pharm Sci. 2021;24:246-57. doi: 10.18433/jpps31668. PubMed PMID: 34048671.
  23. Bhattacharyya A, Kumar S, Sarma P, Kaur H, Prajapat M, Shekhar N, et al. Safety and efficacy of lopinavir/ritonavir combination in COVID-19: A systematic review, meta-analysis, and meta-regression analysis. Indian J Pharmacol. 2020;52:313-23. doi: 10.4103/ijp.IJP_627_20. PubMed PMID: 33078733; PubMed Central PMCID: PMCPMC7722914.
  24. McCreary EK, Angus DC. Efficacy of Remdesivir in COVID-19. JAMA. 2020;324:1041-2. doi: 10.1001/jama.2020.16337. PubMed PMID: 32821934.
  25. Singh S, Khera D, Chugh A, Khera PS, Chugh VK. Efficacy and safety of remdesivir in COVID-19 caused by SARS-CoV-2: a systematic review and meta-analysis. BMJ Open. 2021;11:e048416. doi: 10.1136/bmjopen-2020-048416. PubMed PMID: 34168031; PubMed Central PMCID: PMCPMC8228818.
  26. Sheahan TP, Sims AC, Leist SR, Schafer A, Won J, Brown AJ, et al. Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV. Nat Commun. 2020;11:222. doi: 10.1038/s41467-019-13940-6. PubMed PMID: 31924756; PubMed Central PMCID: PMCPMC6954302.
  27. Vitiello A, Ferrara F, Porta R. Remdesivir and COVID-19 infection, therapeutic benefits or unnecessary risks? Ir J Med Sci. 2021;190:1637-8. doi: 10.1007/s11845-020-02482-2. PubMed PMID: 33433843; PubMed Central PMCID: PMCPMC7801863.
  28. National Institute of Health [Internet]. Remdesivir. c2021 [updated 19 Oct 2021]. Available from: https://www.covid19treatmentguidelines.nih.gov/therapies/antiviral-therapy/remdesivir/.
  29. Beigel JH, Tomashek KM, Dodd LE, Mehta AK, Zingman BS, Kalil AC, et al. Remdesivir for the Treatment of Covid-19 - Final Report. N Engl J Med. 2020;383:1813-26. doi: 10.1056/NEJMoa2007764. PubMed PMID: 32445440; PubMed Central PMCID: PMCPMC7262788.
  30. National Institute of Health [Internet]. Therapeutic Management of Hospitalized Adults With COVID-19. c2021 [updated 19 Oct 2021]. Available from: https://www.covid19treatmentguidelines.nih.gov/management/clinical-management/hospitalized-adults--therapeutic-management/
  31. Kalil AC, Patterson TF, Mehta AK, Tomashek KM, Wolfe CR, Ghazaryan V, et al. Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19. N Engl J Med. 2021;384:795-807. doi: 10.1056/NEJMoa2031994. PubMed PMID: 33306283; PubMed Central PMCID: PMCPMC7745180.
  32. Burwick RM, Yawetz S, Stephenson KE, Collier AY, Sen P, Blackburn BG, et al. Compassionate Use of Remdesivir in Pregnant Women With Severe Coronavirus Disease 2019. Clin Infect Dis. 2021;73:e3996-e4004. doi: 10.1093/cid/ciaa1466. PubMed PMID: 33031500; PubMed Central PMCID: PMCPMC7797739.
  33. Cai Q, Yang M, Liu D, Chen J, Shu D, Xia J, et al. Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study. Engineering (Beijing). 2020;6:1192-8. doi: 10.1016/j.eng.2020.03.007. PubMed PMID: 32346491; PubMed Central PMCID: PMCPMC7185795.
  34. Doi Y, Hibino M, Hase R, Yamamoto M, Kasamatsu Y, Hirose M, et al. A Prospective, Randomized, Open-Label Trial of Early versus Late Favipiravir Therapy in Hospitalized Patients with COVID-19. Antimicrob Agents Chemother. 2020;64. doi: 10.1128/AAC.01897-20. PubMed PMID: 32958718; PubMed Central PMCID: PMCPMC7674035.
  35. Zhang W, Zhao Y, Zhang F, Wang Q, Li T, Liu Z, et al. The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): The Perspectives of clinical immunologists from China. Clin Immunol. 2020;214:108393. doi: 10.1016/j.clim.2020.108393. PubMed PMID: 32222466; PubMed Central PMCID: PMCPMC7102614.
  36. Stebbing J, Phelan A, Griffin I, Tucker C, Oechsle O, Smith D, et al. COVID-19: combining antiviral and anti-inflammatory treatments. Lancet Infect Dis. 2020;20:400-2. doi: 10.1016/S1473-3099(20)30132-8. PubMed PMID: 32113509; PubMed Central PMCID: PMCPMC7158903.
  37. Wijaya I, Andhika R, Huang I, Purwiga A, Budiman KY, Bashari MH, et al. The use of Janus Kinase inhibitors in hospitalized patients with COVID-19: Systematic review and meta-analysis. Clin Epidemiol Glob Health. 2021;11:100755. doi: 10.1016/j.cegh.2021.100755. PubMed PMID: 33969237; PubMed Central PMCID: PMCPMC8088409.
  38. Marconi VC, Ramanan AV, de Bono S, Kartman CE, Krishnan V, Liao R, et al. Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial. Lancet Respir Med. 2021;9:1407-18. doi: 10.1016/S2213-2600(21)00331-3. PubMed PMID: 34480861; PubMed Central PMCID: PMCPMC8409066.
  39. Guimaraes PO, Quirk D, Furtado RH, Maia LN, Saraiva JF, Antunes MO, et al. Tofacitinib in Patients Hospitalized with Covid-19 Pneumonia. N Engl J Med. 2021;385:406-15. doi: 10.1056/NEJMoa2101643. PubMed PMID: 34133856; PubMed Central PMCID: PMCPMC8220898.
  40. National Institute of Health [Internet]. Kinase Inhibitors: Janus Kinase Inhibitors and Bruton’s Tyrosine Kinase Inhibitors. c2021 [updated 19 Oct 2021]. Available from: https://www.covid19treatmentguidelines.nih.gov/therapies/immunomodulators/kinase-inhibitors/
  41. Sanders JM, Monogue ML, Jodlowski TZ, Cutrell JB. Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19): A Review. JAMA. 2020;323:1824-36. doi: 10.1001/jama.2020.6019. PubMed PMID: 32282022.
  42. Hui DS. Systemic Corticosteroid Therapy May Delay Viral Clearance in Patients with Middle East Respiratory Syndrome Coronavirus Infection. Am J Respir Crit Care Med. 2018;197:700-1. doi: 10.1164/rccm.201712-2371ED. PubMed PMID: 29227752.
  43. Auyeung TW, Lee JS, Lai WK, Choi CH, Lee HK, Lee JS, et al. The use of corticosteroid as treatment in SARS was associated with adverse outcomes: a retrospective cohort study. J Infect. 2005;51:98-102. doi: 10.1016/j.jinf.2004.09.008. PubMed PMID: 16038758; PubMed Central PMCID: PMCPMC7132384.
  44. Zha L, Li S, Pan L, Tefsen B, Li Y, French N, et al. Corticosteroid treatment of patients with coronavirus disease 2019 (COVID-19). Med J Aust. 2020;212:416-20. doi: 10.5694/mja2.50577. PubMed PMID: 32266987; PubMed Central PMCID: PMCPMC7262211.
  45. Biffl WL, Moore FA, Moore EE, Haenel JB, McIntyre RC, Jr., Burch JM. Are corticosteroids salvage therapy for refractory acute respiratory distress syndrome? Am J Surg. 1995;170:591-5. doi: 10.1016/s0002-9610(99)80022-1. PubMed PMID: 7492007.
  46. Veronese N, Demurtas J, Yang L, Tonelli R, Barbagallo M, Lopalco P, et al. Use of Corticosteroids in Coronavirus Disease 2019 Pneumonia: A Systematic Review of the Literature. Front Med (Lausanne). 2020;7:170. doi: 10.3389/fmed.2020.00170. PubMed PMID: 32391369; PubMed Central PMCID: PMCPMC7193030.
  47. Shang L, Zhao J, Hu Y, Du R, Cao B. On the use of corticosteroids for 2019-nCoV pneumonia. Lancet. 2020;395:683-4. doi: 10.1016/S0140-6736(20)30361-5. PubMed PMID: 32122468; PubMed Central PMCID: PMCPMC7159292.
  48. Group RC, Horby P, Lim WS, Emberson JR, Mafham M, Bell JL, et al. Dexamethasone in Hospitalized Patients with Covid-19. N Engl J Med. 2021;384:693-704. doi: 10.1056/NEJMoa2021436. PubMed PMID: 32678530; PubMed Central PMCID: PMCPMC7383595.
  49. Piccica M, Lagi F, Trotta M, Spinicci M, Zammarchi L, Bartoloni A, et al. High-dose steroids for the treatment of severe COVID-19. Intern Emerg Med. 2021;16:1395-9. doi: 10.1007/s11739-021-02707-x. PubMed PMID: 33856664; PubMed Central PMCID: PMCPMC8047517.
  50. National Institute of Health [Internet]. Corticosteroids. c2021 [updated 19 Oct 2021]. Available from: https://www.covid19treatmentguidelines.nih.gov/therapies/immunomodulators/corticosteroids/
  51. Tuccori M, Convertino I, Ferraro S, Valdiserra G, Cappello E, Fini E, et al. An overview of the preclinical discovery and development of bamlanivimab for the treatment of novel coronavirus infection (COVID-19): reasons for limited clinical use and lessons for the future. Expert Opin Drug Discov. 2021;16:1403-14. doi: 10.1080/17460441.2021.1960819. PubMed PMID: 34304682; PubMed Central PMCID: PMCPMC8353660.
  52. Marovich M, Mascola JR, Cohen MS. Monoclonal Antibodies for Prevention and Treatment of COVID-19. JAMA. 2020;324:131-2. doi: 10.1001/jama.2020.10245. PubMed PMID: 32539093.
  53. Food and Drug Administration [Internet]. Fact sheet for healthcare providers: emergency use authorization (EUA) of bamlanivimab and etesevimab. c2021. Available from: https://www.fda.gov/media/145802/download
  54. Lloyd EC, Gandhi TN, Petty LA. Monoclonal Antibodies for COVID-19. JAMA. 2021;325:1015. doi: 10.1001/jama.2021.1225. PubMed PMID: 33544136.
  55. Bariola JR, McCreary EK, Wadas RJ, Kip KE, Marroquin OC, Minnier T, et al. Impact of Bamlanivimab Monoclonal Antibody Treatment on Hospitalization and Mortality Among Nonhospitalized Adults With Severe Acute Respiratory Syndrome Coronavirus 2 Infection. Open Forum Infect Dis. 2021;8:254. doi: 10.1093/ofid/ofab254. PubMed PMID: 34250192; PubMed Central PMCID: PMCPMC8241472.
  56. Zhang W, Zhao Y, Zhang F, Wang Q, Li T, Liu Z, et al. The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): The Perspectives of clinical immunologists from China. Clin Immunol. 2020;214:108393. doi: 10.1016/j.clim.2020.108393. PubMed PMID: 32222466; PubMed Central PMCID: PMCPMC7102614.
  57. Febbraio MA, Rose-John S, Pedersen BK. Is interleukin-6 receptor blockade the Holy Grail for inflammatory diseases? Clin Pharmacol Ther. 2010;87:396-8. doi: 10.1038/clpt.2010.1. PubMed PMID: 20305672.
  58. Gordon AC, Angus DC, Derde LPG. Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19. Reply. N Engl J Med. 2021;385:1147-9. doi: 10.1056/NEJMc2108482. PubMed PMID: 34407335.
  59. Group RC. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet. 2021;397:1637-45. doi: 10.1016/S0140-6736(21)00676-0. PubMed PMID: 33933206; PubMed Central PMCID: PMCPMC8084355.
  60. Rosas IO, Brau N, Waters M, Go RC, Hunter BD, Bhagani S, et al. Tocilizumab in Hospitalized Patients with Severe Covid-19 Pneumonia. N Engl J Med. 2021;384:1503-16. doi: 10.1056/NEJMoa2028700. PubMed PMID: 33631066; PubMed Central PMCID: PMCPMC7953459.
  61. National Institute og Health [Internet]. Interleukin-6 Inhibitors: 2021 [updated 19 Oct 2021]. Available from: https://www.covid19treatmentguidelines.nih.gov/therapies/immunomodulators/interleukin-6-inhibitors/
  62. Du J, Li H, Lian J, Zhu X, Qiao L, Lin J. Stem cell therapy: a potential approach for treatment of influenza virus and coronavirus-induced acute lung injury. Stem Cell Res Ther. 2020;11:192. doi: 10.1186/s13287-020-01699-3. PubMed PMID: 32448377; PubMed Central PMCID: PMCPMC7245626.
  63. Uccelli A, de Rosbo NK. The immunomodulatory function of mesenchymal stem cells: mode of action and pathways. Ann N Y Acad Sci. 2015;1351:114-26. doi: 10.1111/nyas.12815. PubMed PMID: 26152292.
  64. Ben-Mordechai T, Palevski D, Glucksam-Galnoy Y, Elron-Gross I, Margalit R, Leor J. Targeting macrophage subsets for infarct repair. J Cardiovasc Pharmacol Ther. 2015;20:36-51. doi: 10.1177/1074248414534916. PubMed PMID: 24938456.
  65. Cardenes N, Aranda-Valderrama P, Carney JP, Sellares Torres J, Alvarez D, Kocyildirim E, et al. Cell therapy for ARDS: efficacy of endobronchial versus intravenous administration and biodistribution of MAPCs in a large animal model. BMJ Open Respir Res. 2019;6:e000308. doi: 10.1136/bmjresp-2018-000308. PubMed PMID: 30713713; PubMed Central PMCID: PMCPMC6339992.
  66. Zheng G, Huang L, Tong H, Shu Q, Hu Y, Ge M, et al. Treatment of acute respiratory distress syndrome with allogeneic adipose-derived mesenchymal stem cells: a randomized, placebo-controlled pilot study. Respir Res. 2014;15:39. doi: 10.1186/1465-9921-15-39. PubMed PMID: 24708472; PubMed Central PMCID: PMCPMC3994204.
  67. Soleymaninejadian E, Pramanik K, Samadian E. Immunomodulatory properties of mesenchymal stem cells: cytokines and factors. Am J Reprod Immunol. 2012;67:1-8. doi: 10.1111/j.1600-0897.2011.01069.x. PubMed PMID: 21951555.
  68. Uccelli A, Pistoia V, Moretta L. Mesenchymal stem cells: a new strategy for immunosuppression? Trends Immunol. 2007;28:219-26. doi: 10.1016/j.it.2007.03.001. PubMed PMID: 17400510.
  69. Basiri A, Pazhouhnia Z, Beheshtizadeh N, Hoseinpour M, Saghazadeh A, Rezaei N. Regenerative Medicine in COVID-19 Treatment: Real Opportunities and Range of Promises. Stem Cell Rev Rep. 2021;17:163-75. doi: 10.1007/s12015-020-09994-5. PubMed PMID: 32564256; PubMed Central PMCID: PMCPMC7305935.
  70. Leng Z, Zhu R, Hou W, Feng Y, Yang Y, Han Q, et al. Transplantation of ACE2(-) Mesenchymal Stem Cells Improves the Outcome of Patients with COVID-19 Pneumonia. Aging Dis. 2020;11:216-28. doi: 10.14336/AD.2020.0228. PubMed PMID: 32257537; PubMed Central PMCID: PMCPMC7069465.
  71. Bari E, Ferrarotti I, Saracino L, Perteghella S, Torre ML, Corsico AG. Mesenchymal Stromal Cell Secretome for Severe COVID-19 Infections: Premises for the Therapeutic Use. Cells. 2020;9. doi: 10.3390/cells9040924. PubMed PMID: 32283815; PubMed Central PMCID: PMCPMC7226831.
  72. Rezakhani L, Kelishadrokhi AF, Soleimanizadeh A, Rahmati S. Mesenchymal stem cell (MSC)-derived exosomes as a cell-free therapy for patients Infected with COVID-19: Real opportunities and range of promises. Chem Phys Lipids. 2021;234:105009. doi: 10.1016/j.chemphyslip.2020.105009. PubMed PMID: 33189639; PubMed Central PMCID: PMCPMC7658620.
  73. Chen L, Xiong J, Bao L, Shi Y. Convalescent plasma as a potential therapy for COVID-19. Lancet Infect Dis. 2020;20:398-400. doi: 10.1016/S1473-3099(20)30141-9. PubMed PMID: 32113510; PubMed Central PMCID: PMCPMC7128218.
  74. Barlow A, Landolf KM, Barlow B, Yeung SYA, Heavner JJ, Claassen CW, et al. Review of Emerging Pharmacotherapy for the Treatment of Coronavirus Disease 2019. Pharmacotherapy. 2020;40:416-37. doi: 10.1002/phar.2398. PubMed PMID: 32259313; PubMed Central PMCID: PMCPMC7262196.
  75. Duan K, Liu B, Li C, Zhang H, Yu T, Qu J, et al. Effectiveness of convalescent plasma therapy in severe COVID-19 patients. Proc Natl Acad Sci U S A. 2020;117:9490-6. doi: 10.1073/pnas.2004168117. PubMed PMID: 32253318; PubMed Central PMCID: PMCPMC7196837.
  76. Rojas M, Rodriguez Y, Monsalve DM, Acosta-Ampudia Y, Camacho B, Gallo JE, et al. Convalescent plasma in Covid-19: Possible mechanisms of action. Autoimmun Rev. 2020;19:102554. doi: 10.1016/j.autrev.2020.102554. PubMed PMID: 32380316; PubMed Central PMCID: PMCPMC7198427.
  77. Brown BL, McCullough J. Treatment for emerging viruses: Convalescent plasma and COVID-19. Transfus Apher Sci. 2020;59:102790. doi: 10.1016/j.transci.2020.102790. PubMed PMID: 32345485; PubMed Central PMCID: PMCPMC7194745.
  78. Joyner MJ, Carter RE, Senefeld JW, Klassen SA, Mills JR, Johnson PW, et al. Convalescent Plasma Antibody Levels and the Risk of Death from Covid-19. N Engl J Med. 2021;384:1015-27. doi: 10.1056/NEJMoa2031893. PubMed PMID: 33523609; PubMed Central PMCID: PMCPMC7821984.
  79. Klassen SA, Senefeld J, Johnson PW, Carter RE, Wiggins CC, Shoham S, et al. The Effect of Convalescent Plasma Therapy on COVID-19 Patient Mortality: Systematic Review and Meta-analysis. medRxiv. 2021. doi: 10.1101/2020.07.29.20162917. PubMed PMID: 33140056; PubMed Central PMCID: PMCPMC7605561.
  80. Casadevall A, Dragotakes Q, Johnson PW, Senefeld JW, Klassen SA, Wright RS, et al. Convalescent plasma use in the USA was inversely correlated with COVID-19 mortality. Elife. 2021;10. doi: 10.7554/eLife.69866. PubMed PMID: 34085928; PubMed Central PMCID: PMCPMC8205484.
  81. Zhou W, Liu Y, Tian D, Wang C, Wang S, Cheng J, et al. Potential benefits of precise corticosteroids therapy for severe 2019-nCoV pneumonia. Signal Transduct Target Ther. 2020;5:18. doi: 10.1038/s41392-020-0127-9. PubMed PMID: 32296012; PubMed Central PMCID: PMCPMC7035340.
  82. Bloch EM, Shoham S, Casadevall A, Sachais BS, Shaz B, Winters JL, et al. Deployment of convalescent plasma for the prevention and treatment of COVID-19. J Clin Invest. 2020;130:2757-65. doi: 10.1172/JCI138745. PubMed PMID: 32254064; PubMed Central PMCID: PMCPMC7259988.
  83. O’Donnell MR, Grinsztejn B, Cummings MJ, Justman JE, Lamb MR, Eckhardt CM, et al. A randomized double-blind controlled trial of convalescent plasma in adults with severe COVID-19. J Clin Invest. 2021;131. doi: 10.1172/JCI150646. PubMed PMID: 33974559; PubMed Central PMCID: PMCPMC8245169.
  84. Piechotta V, Chai KL, Valk SJ, Doree C, Monsef I, Wood EM, et al. Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a living systematic review. Cochrane Database Syst Rev. 2020;7:CD013600. doi: 10.1002/14651858.CD013600.pub2. PubMed PMID: 32648959; PubMed Central PMCID: PMCPMC7389743.
  85. Bakhtawar N, Usman M, Khan MMU. Convalescent Plasma Therapy and Its Effects On COVID-19 Patient Outcomes: A Systematic Review of Current Literature. Cureus. 2020;12:e9535. doi: 10.7759/cureus.9535. PubMed PMID: 32905148; PubMed Central PMCID: PMCPMC7465934.
  86. World Health Organization [Internet]. COVID-19 vaccine tracker and landscape. c2021. [updated 24 Oct 2021]. Available from: https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines
  87. World Health Organization [Internet]. 7 Vaccines Approved for Use by WHO. c2021. [updated 1 Nov 2021]. Available from: https://covid19.trackvaccines.org/agency/who/
  88. Nagy A, Alhatlani B. An overview of current COVID-19 vaccine platforms. Comput Struct Biotechnol J. 2021;19:2508-17. doi: 10.1016/j.csbj.2021.04.061. PubMed PMID: 33936564; PubMed Central PMCID: PMCPMC8076774.
  89. Food and Drug Administration [Internet]. COVID-19 Vaccines. c2021 [updated 24 Oct 2021]. Available from: https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/covid-19-vaccines
  90. Sharma A, Krause A, Worgall S. Recent developments for Pseudomonas vaccines. Hum Vaccin. 2011;7:999-1011. doi: 10.4161/hv.7.10.16369. PubMed PMID: 21941090; PubMed Central PMCID: PMCPMC3360073.
  91. Jiang S, Bottazzi ME, Du L, Lustigman S, Tseng CT, Curti E, et al. Roadmap to developing a recombinant coronavirus S protein receptor-binding domain vaccine for severe acute respiratory syndrome. Expert Rev Vaccines. 2012;11:1405-13. doi: 10.1586/erv.12.126. PubMed PMID: 23252385; PubMed Central PMCID: PMCPMC3586247.
  92. Bolles M, Deming D, Long K, Agnihothram S, Whitmore A, Ferris M, et al. A double-inactivated severe acute respiratory syndrome coronavirus vaccine provides incomplete protection in mice and induces increased eosinophilic proinflammatory pulmonary response upon challenge. J Virol. 2011;85:12201-15. doi: 10.1128/JVI.06048-11. PubMed PMID: 21937658; PubMed Central PMCID: PMCPMC3209347.
  93. Tseng CT, Sbrana E, Iwata-Yoshikawa N, Newman PC, Garron T, Atmar RL, et al. Immunization with SARS coronavirus vaccines leads to pulmonary immunopathology on challenge with the SARS virus. PLoS One. 2012;7:e35421. doi: 10.1371/journal.pone.0035421. PubMed PMID: 22536382; PubMed Central PMCID: PMCPMC3335060.
  94. Weingartl H, Czub M, Czub S, Neufeld J, Marszal P, Gren J, et al. Immunization with modified vaccinia virus Ankara-based recombinant vaccine against severe acute respiratory syndrome is associated with enhanced hepatitis in ferrets. J Virol. 2004;78:12672-6. doi: 10.1128/JVI.78.22.12672-12676.2004. PubMed PMID: 15507655; PubMed Central PMCID: PMCPMC525089.
  95. Rawat K, Kumari P, Saha L. COVID-19 vaccine: A recent update in pipeline vaccines, their design and development strategies. Eur J Pharmacol. 2021;892:173751. doi: 10.1016/j.ejphar.2020.173751. PubMed PMID: 33245898; PubMed Central PMCID: PMCPMC7685956.
  96. Kaur SP, Gupta V. COVID-19 Vaccine: A comprehensive status report. Virus Res. 2020;288:198114. doi: 10.1016/j.virusres.2020.198114. PubMed PMID: 32800805; PubMed Central PMCID: PMCPMC7423510.
  97. Liang JG, Su D, Song TZ, Zeng Y, Huang W, Wu J, et al. S-Trimer, a COVID-19 subunit vaccine candidate, induces protective immunity in nonhuman primates. Nat Commun. 2021;12:1346. doi: 10.1038/s41467-021-21634-1. PubMed PMID: 33649323; PubMed Central PMCID: PMCPMC7921634.
  98. Tian JH, Patel N, Haupt R, Zhou H, Weston S, Hammond H, et al. SARS-CoV-2 spike glycoprotein vaccine candidate NVX-CoV2373 immunogenicity in baboons and protection in mice. Nat Commun. 2021;12:372. doi: 10.1038/s41467-020-20653-8. PubMed PMID: 33446655; PubMed Central PMCID: PMCPMC7809486.
  99. Tai W, He L, Zhang X, Pu J, Voronin D, Jiang S, et al. Characterization of the receptor-binding domain (RBD) of 2019 novel coronavirus: implication for development of RBD protein as a viral attachment inhibitor and vaccine. Cell Mol Immunol. 2020;17:613-20. doi: 10.1038/s41423-020-0400-4. PubMed PMID: 32203189; PubMed Central PMCID: PMCPMC7091888.
  100. Yang S, Li Y, Dai L, Wang J, He P, Li C, et al. Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD-based protein subunit vaccine (ZF2001) against COVID-19 in adults: two randomised, double-blind, placebo-controlled, phase 1 and 2 trials. Lancet Infect Dis. 2021;21:1107-19. doi: 10.1016/S1473-3099(21)00127-4. PubMed PMID: 33773111; PubMed Central PMCID: PMCPMC7990482.
  101. Pardi N, Hogan MJ, Porter FW, Weissman D. mRNA vaccines - a new era in vaccinology. Nat Rev Drug Discov. 2018;17:261-79. doi: 10.1038/nrd.2017.243. PubMed PMID: 29326426; PubMed Central PMCID: PMCPMC5906799.
  102. Liu MA. A Comparison of Plasmid DNA and mRNA as Vaccine Technologies. Vaccines (Basel). 2019;7. doi: 10.3390/vaccines7020037. PubMed PMID: 31022829; PubMed Central PMCID: PMCPMC6631684.
  103. Shafaati M, Saidijam M, Soleimani M, Hazrati F, Mirzaei R, Amirheidari B, et al. A brief review on DNA vaccines in the era of COVID-19. Future Virol. 2021. doi: 10.2217/fvl-2021-0170. PubMed PMID: 34858516; PubMed Central PMCID: PMCPMC8629371.
  104. Sheridan C. First COVID-19 DNA vaccine approved, others in hot pursuit. Nat Biotechnol. 2021;39:1479-82. doi: 10.1038/d41587-021-00023-5. PubMed PMID: 34785814.
  105. Azmi F, Ahmad Fuaad AA, Skwarczynski M, Toth I. Recent progress in adjuvant discovery for peptide-based subunit vaccines. Hum Vaccin Immunother. 2014;10:778-96. doi: 10.4161/hv.27332. PubMed PMID: 24300669; PubMed Central PMCID: PMCPMC4130256.
  106. Ahmed SF, Quadeer AA, McKay MR. Preliminary Identification of Potential Vaccine Targets for the COVID-19 Coronavirus (SARS-CoV-2) Based on SARS-CoV Immunological Studies. Viruses. 2020;12. doi: 10.3390/v12030254. PubMed PMID: 32106567; PubMed Central PMCID: PMCPMC7150947.
  107. Rahman MS, Hoque MN, Islam MR, Akter S, Rubayet Ul Alam ASM, Siddique MA, et al. Epitope-based chimeric peptide vaccine design against S, M and E proteins of SARS-CoV-2, the etiologic agent of COVID-19 pandemic: an in silico approach. PeerJ. 2020;8:e9572. doi: 10.7717/peerj.9572. PubMed PMID: 33194329; PubMed Central PMCID: PMCPMC7394063.
  108. Lukashev AN, Zamyatnin AA, Jr. Viral Vectors for Gene Therapy: Current State and Clinical Perspectives. Biochemistry (Mosc). 2016;81:700-8. doi: 10.1134/S0006297916070063. PubMed PMID: 27449616.
  109. Holm MR, Poland GA. Critical aspects of packaging, storage, preparation, and administration of mRNA and adenovirus-vectored COVID-19 vaccines for optimal efficacy. Vaccine. 2021;39:457-9. doi: 10.1016/j.vaccine.2020.12.017. PubMed PMID: 33339671; PubMed Central PMCID: PMCPMC7723768.
  110. Mendonca SA, Lorincz R, Boucher P, Curiel DT. Adenoviral vector vaccine platforms in the SARS-CoV-2 pandemic. NPJ Vaccines. 2021;6:97. doi: 10.1038/s41541-021-00356-x. PubMed PMID: 34354082; PubMed Central PMCID: PMCPMC8342436.
  111. Mahase E. Covid-19: How many variants are there, and what do we know about them? BMJ. 2021;374:n1971. doi: 10.1136/bmj.n1971. PubMed PMID: 34413059.
  112. Harvey WT, Carabelli AM, Jackson B, Gupta RK, Thomson EC, Harrison EM, et al. SARS-CoV-2 variants, spike mutations and immune escape. Nat Rev Microbiol. 2021;19:409-24. doi: 10.1038/s41579-021-00573-0. PubMed PMID: 34075212; PubMed Central PMCID: PMCPMC8167834.
  113. Malik JA, Mulla AH, Farooqi T, Pottoo FH, Anwar S, Rengasamy KRR. Targets and strategies for vaccine development against SARS-CoV-2. Biomed Pharmacother. 2021;137:111254. doi: 10.1016/j.biopha.2021.111254. PubMed PMID: 33550049; PubMed Central PMCID: PMCPMC7843096.
  114. Zhou W, Wang W. Fast-spreading SARS-CoV-2 variants: challenges to and new design strategies of COVID-19 vaccines. Signal Transduct Target Ther. 2021;6:226. doi: 10.1038/s41392-021-00644-x. PubMed PMID: 34108440; PubMed Central PMCID: PMCPMC8187888.
آمار
تعداد مشاهده مقاله: 3,851
تعداد دریافت فایل اصل مقاله: 2,996


سامانه مدیریت نشریات علمی. قدرت گرفته از سیناوب